Search This Blog

Tuesday, November 12, 2019

Prevail Therapeutics EPS misses by $0.11

Prevail Therapeutics (NASDAQ:PRVL): Q3 GAAP EPS of -$0.62 misses by $0.11.
Cash and cash equivalents of $183.07M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)